HEPASTEM



NAME OF DRUG : HEPASTEM

ALSO KNOWN AS : HEPASTEM

LABORATORY : PROMETHERA

STATUS AND ADVANCEMENT

Type of drug : human liver derived mesenchymal stem

Clinical trials advancement : Preclinic

Estimated time to market : 135 months.

LABORATORY ABSTRACT ON THE DRUG

HepaStem is a human liver derived mesenchymal stem cell with the potential to differentiate into hepatocyte like cells and displaying anti-inflammatory and anti-fibrotic properties. HepaStem is today developed in ACLF and NASH/Fibrosis. Promethera Biosciences has started a phase IIa trial in ACLF to establish the safety of the peripheral intravenous infusion of HepaStem as a primary endpoint and explore clinical and biological parameters as secondary endpoints.

RECENT NEWS ON HEPASTEM

SOME PUBLICATIONS RELATED WITH HEPASTEM

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH HEPASTEM


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE